Brokerages Set Novo Nordisk A/S (NYSE:NVO) Target Price at $65.56

Novo Nordisk A/S (NYSE:NVO) has received a consensus recommendation of “Hold” from the twenty-four ratings firms that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, nineteen have issued a hold rating and four have assigned a buy rating to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $65.5625.

Several equities analysts have recently weighed in on the stock. Deutsche Bank Aktiengesellschaft lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Monday, February 23rd. Jefferies Financial Group upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a report on Thursday, February 12th. Sanford C. Bernstein started coverage on Novo Nordisk A/S in a report on Wednesday, March 18th. They set an “outperform” rating and a $175.00 price objective for the company. Weiss Ratings cut Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday, March 18th. Finally, CICC Research assumed coverage on Novo Nordisk A/S in a research note on Friday, January 9th. They set an “outperform” rating and a $73.50 price objective on the stock.

Trending Headlines about Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo launched a multi‑month subscription program for Wegovy to lower out‑of‑pocket cost and improve adherence, which could bolster retail uptake and stabilize revenue from self‑pay patients. Slash Your Wegovy Costs: Novo Nordisk Reveals First-Ever Subscription Plan
• Positive Sentiment: Company cites cross‑trial data (ORION) showing oral Wegovy produced greater mean weight loss and fewer discontinuations vs. Lilly’s new pill — a claim that, if borne out commercially, helps defend market share in the oral GLP‑1 segment. Novo Nordisk says Wegovy pill outperforms Lilly’s oral GLP-1 in cross-trial comparison
• Positive Sentiment: Wegovy was cleared by a UK drug‑pricing body for heart‑disease prevention, expanding the eligible patient pool by ~1.2M people — a potential medium‑term sales tailwind in the U.K. Novo’s Wegovy cleared by UK drug price watchdog for heart disease, expanding access by 1.2 million people
• Positive Sentiment: Pipeline progress — including once‑a‑week insulin work and early triple‑agonist studies — supports longer‑term growth optionality beyond current GLP‑1 competition. What Does Novo Nordisk’s (NVO) Once A Week Insulin Mean For Investors?
• Neutral Sentiment: BMO Capital reiterated a Market Perform (hold) rating with a $45 price target — a sign analysts see recovery potential but not an immediate buy catalyst. BMO Capital Maintains a Hold Rating on Novo Nordisk (NVO)
• Neutral Sentiment: Market commentary notes shares have at times held up despite new competition, suggesting investors believe some threats are already priced in. Novo Nordisk shares resilient as FDA approves Eli Lilly GLP-1 weight-loss pill to intensify competition
• Negative Sentiment: Eli Lilly’s oral GLP‑1 (Foundayo) gained FDA approval and is launching, creating a fierce new competitor in the oral obesity market and pressuring expectations for Novo’s market share and pricing. Wall Street sees multi-billion dollar debut for Lilly’s obesity pill despite Novo lead
• Negative Sentiment: Low‑cost generic semaglutide in India forced Novo to cut Wegovy/Ozempic prices by as much as 48% in that market, highlighting pricing vulnerability where generics emerge. Novo Nordisk Shares Down 43% in a Year as Generic Rivals Force 48% Price Cuts
• Negative Sentiment: Policy risk: U.S. proposals to impose heavy tariffs on branded drugs could raise costs or complicate pricing strategies for multinational drugmakers. Trump administration prepares up to 100% pharmaceutical tariffs on some imported drugs
• Negative Sentiment: Valuation and sentiment questions after a ~43% Y/Y drop: investors are re‑pricing Novo on the view that competitive erosion, price competition and upcoming patent expiries will constrain near‑term growth. Is Novo Nordisk (NYSE:NVO) Pricing Fair After A 43% One Year Share Price Decline?

Institutional Trading of Novo Nordisk A/S

Institutional investors and hedge funds have recently modified their holdings of the business. Martin Capital Partners LLC lifted its stake in shares of Novo Nordisk A/S by 53.8% during the 3rd quarter. Martin Capital Partners LLC now owns 117,577 shares of the company’s stock valued at $6,524,000 after buying an additional 41,129 shares in the last quarter. Smith Chas P & Associates PA Cpas lifted its position in shares of Novo Nordisk A/S by 105.3% during the third quarter. Smith Chas P & Associates PA Cpas now owns 405,425 shares of the company’s stock worth $22,497,000 after acquiring an additional 207,959 shares in the last quarter. Clifford Swan Investment Counsel LLC grew its position in shares of Novo Nordisk A/S by 13.7% in the third quarter. Clifford Swan Investment Counsel LLC now owns 311,168 shares of the company’s stock valued at $17,267,000 after purchasing an additional 37,453 shares in the last quarter. Markel Group Inc. lifted its holdings in Novo Nordisk A/S by 4.9% during the 3rd quarter. Markel Group Inc. now owns 2,368,649 shares of the company’s stock worth $131,436,000 after purchasing an additional 110,061 shares in the last quarter. Finally, Cantor Fitzgerald Investment Advisors L.P. purchased a new position in Novo Nordisk A/S during the 3rd quarter valued at about $1,294,000. 11.54% of the stock is owned by hedge funds and other institutional investors.

Novo Nordisk A/S Price Performance

Shares of NVO opened at $36.92 on Friday. Novo Nordisk A/S has a 52-week low of $35.12 and a 52-week high of $81.44. The company has a debt-to-equity ratio of 0.61, a quick ratio of 0.57 and a current ratio of 0.80. The business’s 50 day moving average price is $43.43 and its two-hundred day moving average price is $49.74. The firm has a market cap of $164.86 billion, a PE ratio of 10.64, a price-to-earnings-growth ratio of 8.75 and a beta of 0.73.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Tuesday, February 3rd. The company reported $1.01 EPS for the quarter, topping the consensus estimate of $0.90 by $0.11. The company had revenue of $12.43 billion during the quarter, compared to the consensus estimate of $11.97 billion. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. On average, equities analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Dividend Announcement

The company also recently announced a dividend, which will be paid on Wednesday, April 8th. Shareholders of record on Monday, March 30th will be given a dividend of $1.2751 per share. The ex-dividend date of this dividend is Monday, March 30th. This represents a dividend yield of 723.0%. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 50.43%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.